Clinical implications of peripheral blood biomarkers in patients with advanced breast cancer treated with trastuzumab emtansine and trastuzumab deruxtecan
Immune status may influence treatment outcomes in the T-DM1 and T-DXd (HER2-low) groups. Conversely, in the T-DXd (HER2-positive) group, the treatment outcome was independent of immune status.
Authors
- Ayumu Mitsuyoshi
- Tomoko Higuchi
- Arisa Nishimukai
- Haruka Kanaoka
- Masayuki Nagahashi (ORCID: https://orcid.org/0000-0002-9308-448X)
- Yasuo Miyoshi (ORCID: https://orcid.org/0000-0001-8535-4008)
- Akira Hattori (ORCID: https://orcid.org/0000-0001-5509-2326)
- Junko Tsuchida (ORCID: https://orcid.org/0000-0001-7129-3304)
- Aoi Oshiro
- Yusa Togashi
- Gen Sugimoto
Institutions
- Hyogo Medical University (JP)
- Hyogo University (JP)
Publication Details
- Journal
- International Journal of Clinical Oncology
- Published
- 2025-04-29
- DOI
- https://doi.org/10.1007/s10147-025-02768-4
- Citations
- 2
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- Japan Society for the Promotion of Science